Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease (AD), affected neurons accumulate beta amyloid protein, components of which can induce mouse microglia to express the high-output isoform of nitric oxide synthase (NOS2) in vitro. Products of NOS2 can be neurotoxic. In mice, NOS2 is normally suppressed by transforming growth factor beta 1 (TGF-beta 1). Expression of TGF-beta 1 is decreased in brains from AD patients, a situation that might be permissive for accumulation of NOS2. Accordingly, we investigated the expression of NOS2 in patients with AD, using three monospecific antibodies: a previously described polyclonal and two new monoclonal antibodies. Neurofibrillary tangle-bearing neurons and neuropil threads contained NOS2 in brains from each of 11 AD patients ranging in age from 47 to 81 years. NOS2 was undetectable in brains from 6 control subjects aged 23-72 years, but was expressed in small amounts in 3 control subjects aged 77-87 years. Thus, human neurons can express NOS2 in vivo. The high-output pathway of NO production may contribute to pathogenesis in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“The appearance of AD-like pathology in mice transgenic for A13 precursor protein (2)”
BackgroundConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Nitric oxide, a novel neuronal messenger
Bredt, D. S., & Snyder, S. H. (1992) · Neuron · doi:10.1016/0896-6273(92)90104-l · Cited by 1,846
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314 · cited 3×
“In vitro, cytokines, microbial products, and A[~ peptides, usually in combination, have induced N O S 2 in rodent and human microglia and astrocytes (5-7).”
BackgroundMolecular cloning and expression of inducible nitric oxide synthase from human hepatocytes.
Geller, D. A., Lowenstein, C. J., Shapiro, R. A., Nussler, A. K., Di Silvio, M., Wang, S. C., Nakayama, D. K., Simmons, R. L., Snyder, S. H., & Billiar, T. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3491 · Cited by 821
Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide.
Merrill, J. E., Ignarro, L. J., Sherman, M. P., Melinek, J., & Lane, T. E. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.4.2132 · Cited by 781
Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species.
Wink, D. A., Hanbauer, I., Krishna, M. C., DeGraff, W., Gamson, J., & Mitchell, J. B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.9813 · Cited by 767
Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains
Bö, L., Dawson, T. M., Wesselingh, S., Möurk, S., Choi, S., Kong, P. A., Hanley, D., & Trapp, B. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360515 · Cited by 567
Cited by
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
Innate immunity in Alzheimer's disease
Heneka, M. T., Golenbock, D. T., & Latz, E. (2015) · Nature Immunology · doi:10.1038/ni.3102 · Cited by 902
Inducible nitric oxide synthase: Regulation, structure, and inhibition
Cinelli, M. A., Do, H. T., Miley, G. P., & Silverman, R. B. (2020) · Medicinal Research Reviews · doi:10.1002/med.21599 · Cited by 889
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World Journal · doi:10.1100/2012/756357 · Cited by 839
Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & de Ceballos, M. L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 785
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Beal, M. F. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00780-3 · Cited by 763
Oxidative stress and nitration in neurodegeneration: Cause, effect, or association?
Ischiropoulos, H., & Beckman, J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17638 · Cited by 747
Combs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721
“Importantly, it has been reported that levels of TNFa and neuronal iNOS immunoreactivity are increased in the AD brain (Fillit et al., 1991; Vodovotz et al., 1996; Bruunsgaard et al., 1999; Tarkowski et al., 1999).”
BackgroundInfluentialIadecola, C., Zhang, F., Casey, R., Nagayama, M., & Ross, M. E. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-23-09157.1997 · Cited by 661
INHIBITION OF NITRIC OXIDE SYNTHASE AS A POTENTIAL THERAPEUTIC TARGET
Hobbs, A. J., Higgs, A., & Moncada, S. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.191 · Cited by 596
Inducible nitric oxide synthase in human diseases
Kröncke, K.-D., Fehsel, K., & Kolb-Bachofen, V (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1998.00648.x · Cited by 585
Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2
Knott, C., Stern, G., & Wilkin, G. P. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0914 · Cited by 503
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease
Kaur, D., Sharma, V., & Deshmukh, R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 484
Nitric oxide, mitochondria and neurological disease
Heales, S. J. R., Bolaños, J. P., Stewart, V. C., Brookes, P. S., Land, J. M., & Clark, J. B. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00168-6 · Cited by 476
The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma.
Ramirez, A. I., de Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., López-Cuenca, I., Rojas, P., Triviño, A., & Ramírez, J. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00214 · Cited by 466
Inflammatory Neurodegeneration Mediated by Nitric Oxide, Glutamate, and Mitochondria
Brown, G. C., & Bal-Price, A. (2003) · Molecular Neurobiology · doi:10.1385/mn:27:3:325 · Cited by 461
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
“…demyelinating diseases (Willenborg et al. 1999a, b), cerebral ischemia (del Zoppo et al. 2000), AIDS dementia (Hori et al. 1999), amyotro- phic lateral sclerosis (Almer et al. 1999), and AD (Vodo- votz et al. 1996; Wallace et al. 1997; Weldon et al. 1998; Lee et al. 1999; Heneka et al. 2001).”
BackgroundInfluentialNeurodegenerative disorders: the role of peroxynitrite
Torreilles, F., Salman-Tabcheh, S., Guérin, M.-C., & Torreilles, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00014-4 · Cited by 430
Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation
Kadowaki, H., Nishitoh, H., Urano, F., Sadamitsu, C., Matsuzawa, A., Takeda, K., Masutani, H., Yodoi, J., Urano, Y., Nagano, T., et al. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401528 · Cited by 429
Neuroprotective strategies involving ROS in Alzheimer disease
Dumont, M., & Beal, M. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.026 · Cited by 402
Angeles Muñoz-Fernández, M., & Fresno, M. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00045-8 · Cited by 367
TRANSFORMING GROWTH FACTOR-βS IN NEURODEGENERATIVE DISEASE
FLANDERS, K. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00066-x · Cited by 364
Self-citationMicroglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Truncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt258 · Cited by 341
Nitration of Tyrosine 10 Critically Enhances Amyloid β Aggregation and Plaque Formation
Kummer, M. P., Hermes, M., Delekarte, A., Hammerschmidt, T., Kumar, S., Terwel, D., Walter, J., Pape, H.-C., König, S., Roeber, S., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.001 · Cited by 336
“In line with this, induction of NOS2 expression has been demonstrated in AD (Vodovotz et al., 1996; Heneka et al., 2001) and in the Tg2576 AD mouse model (Rodrigo et al.”
Fibrillar Amyloid-β Peptides Activate Microglia via TLR2: Implications for Alzheimer’s Disease
Jana, M., Palencia, C. A., & Pahan, K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7254 · Cited by 330
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Production of nitric oxide by glial cells: Regulation and potential roles in the CNS
Murphy, S. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000101)29:1<1::aid-glia1>3.0.co;2-n · Cited by 314
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., & Van Leuven, F. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-22 · Cited by 309
“Because iNOS expression and increased nitrotyrosine staining has been attributed to AD before [34,35], APP [V717I] mice also resemble this aspect of neurodegeneration-induced glial inflammation.”
Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldiks, N., Zimmer, A., Hoehn, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4236-05.2006 · Cited by 305
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia
Nogawa, S., Forster, C., Zhang, F., Nagayama, M., Ross, M. E., & Iadecola, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10966 · Cited by 295
Should Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., Woldeyohannes, H. O., Law, C. W. Y., Miranda, A., Fulgosi, D., & Kennedy, S. H. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701653377 · Cited by 277
“For example, the expression of Inducible nitric oxide synthase (iNOS) has been reported to provoke neuronal cell death and its neuronal expression is increased in persons with Alzheimer’s disease (80,81).”
BackgroundHeneka, M. T., Klockgether, T., & Feinstein, D. L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-18-06862.2000 · Cited by 269
Heneka, M. T., Galea, E., Gavriluyk, V., Dumitrescu-Ozimek, L., Daeschner, J., O'Banion, M. K., Weinberg, G., Klockgether, T., & Feinstein, D. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02434.2002 · Cited by 259
Microglia and Alzheimer’s Disease
Merighi, S., Nigro, M., Travagli, A., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112990 · Cited by 236
Nathan, C., Calingasan, N., Nezezon, J., Ding, A., Lucia, M. S., La Perle, K., Fuortes, M., Lin, M., Ehrt, S., Kwon, N. S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051529 · Cited by 214
“In 1996, iNOS was identified in AD lesions (10).”
BackgroundSelf-citationLüth, H.-J., Holzer, M., Gärtner, U., Staufenbiel, M., & Arendt, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02758-5 · Cited by 183
Heneka, M. T., L. Feinstein, D., Galea, E., Gleichmann, M., Wüllner, U., & Klockgether, T. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00192-7 · Cited by 150
Baldacci, F., Lista, S., Cavedo, E., Bonuccelli, U., & Hampel, H. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304217 · Cited by 113
COLTON, C., BROWN, C., COOK, D., NEEDHAM, L., XU, Q., CZAPIGA, M., SAUNDERS, A., SCHMECHEL, D., RASHEED, K., & VITEK, M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00016-7 · Cited by 108
Lüth, H. J., Holzer, M., Gertz, H.-J., & Arendt, T. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02178-2 · Cited by 105
The protective role of nitric oxide in a neurotoxicant-induced demyelinating model
Arnett, H. A., Hellendall, R. P., Matsushima, G. K., Suzuki, K., Laubach, V. E., Sherman, P., & Ting, J. P.-Y. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.427 · Cited by 71
Ahmed, L. A., Darwish, H. A., Abdelsalam, R. M., & Amin, H. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9303-2 · Cited by 55
Ugolini, F., Lana, D., Nardiello, P., Nosi, D., Pantano, D., Casamenti, F., & Giovannini, M. G. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00372 · Cited by 50
Maresin 1 attenuates pro‐inflammatory activation induced by β‐amyloid and stimulates its uptake
Wang, Y., Leppert, A., Tan, S., van der Gaag, B., Li, N., Schultzberg, M., & Hjorth, E. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16098 · Cited by 33
Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Lewis, G. F., Leiter, L. A., MacQueen, G. M., Miranda, A., Fulgosi, D., Konarski, J. Z., & Kennedy, S. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1615 · Cited by 32
“The expression of iNOS has been reported to induce neuronal cell death and its neuronal expression is increased in persons with AD [111,113] .”
Background
Metadata
- Authors
- Vodovotz, Y., Lucia, M. S., Flanders, K. C., Chesler, L., Xie, Q. W., Smith, T. W., Weidner, J., Mumford, R., Webber, R., Nathan, C., Roberts, A. B., Lippa, C. F., & Sporn, M. B.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-10-01
- Volume
- 184
- Issue
- 4
- Pages
- 1425-1433
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2107282184
- Cited by
- 288
- References
- 32
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.